Korea’s CJ Looking To P-CAB, Biosimilars To Double Revenues
This article was originally published in PharmAsia News
Executive Summary
CJ HealthCare, the pharma affiliate of South Korea's CJ Group, is aiming to more than double its annual revenues to KRW1 trillion ($910 million) by 2020 by developing new drugs and biosimilars.